Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Jul;34(1):65–70. doi: 10.1111/j.1365-2125.1992.tb04109.x

Effects of granisetron and haloperidol, alone and in combination, on psychometric performance and the EEG.

T J Leigh 1, C G Link 1, G L Fell 1
PMCID: PMC1381377  PMID: 1321654

Abstract

1. The effects of granisetron (160 micrograms kg-1 body weight) and haloperidol (3 mg) on psychometric performance and the EEG were investigated in a randomised, single-blind, crossover, placebo controlled study of 12 healthy male volunteers. 2. There was evidence that haloperidol impaired psychometric performance; however its effects on the EEG were not clear cut. In contrast there was very little evidence to suggest that granisetron had any impact on performance or the EEG. 3. The findings from this study suggest that granisetron does not impair daytime function and that it can be co-administered with haloperidol without producing unwanted synergistic effects.

Full text

PDF
65

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andrews P. L., Rapeport W. G., Sanger G. J. Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci. 1988 Sep;9(9):334–341. doi: 10.1016/0165-6147(88)90106-x. [DOI] [PubMed] [Google Scholar]
  2. Barnes N. M., Costall B., Ironside J. W., Naylor R. J. Identification of 5-HT3 recognition sites in human brain tissue using [3H]zacopride. J Pharm Pharmacol. 1988 Sep;40(9):668–668. doi: 10.1111/j.2042-7158.1988.tb05338.x. [DOI] [PubMed] [Google Scholar]
  3. Bright-Asare P., El-Bassoussi M. Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux. J Clin Gastroenterol. 1980 Jun;2(2):149–156. doi: 10.1097/00004836-198006000-00008. [DOI] [PubMed] [Google Scholar]
  4. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. The Granisetron Study Group. Eur J Cancer. 1990;26 (Suppl 1):S33–S36. [PubMed] [Google Scholar]
  5. Irwin P. Spectral difference index: a single EEG measure of drug effect. Electroencephalogr Clin Neurophysiol. 1982 Sep;54(3):342–346. doi: 10.1016/0013-4694(82)90184-5. [DOI] [PubMed] [Google Scholar]
  6. Leigh T. J., Link C. G., Fell G. L. Effects of granisetron and lorazepam, alone and in combination, on psychometric performance. Br J Clin Pharmacol. 1991 Mar;31(3):333–336. doi: 10.1111/j.1365-2125.1991.tb05537.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Link C. G., Leigh T. J., Fell G. L. Effects of granisetron and lorazepam, alone and in combination, on the EEG of human volunteers. Br J Clin Pharmacol. 1991 Jan;31(1):93–97. doi: 10.1111/j.1365-2125.1991.tb03863.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Miner W. D., Sanger G. J., Turner D. H. Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer. 1987 Aug;56(2):159–162. doi: 10.1038/bjc.1987.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Wieneke G. H., Verhoeven W. M., Westenberg H. G., de Wilde H., Lopes da Silva F. H., van Praag M., Storm van Leeuwen W. The effects of haloperidol on the EEG spectrum. Psychopharmacology (Berl) 1981;74(1):33–34. doi: 10.1007/BF00431753. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES